These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 7296548

  • 1. Phase I and pharmacokinetic studies of DON.
    Kovach JS, Eagan RT, Powis G, Rubin J, Creagan ET, Moertel CG.
    Cancer Treat Rep; 1981; 65(11-12):1031-6. PubMed ID: 7296548
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma.
    Lynch G, Kemeny N, Casper E.
    Am J Clin Oncol; 1982 Oct; 5(5):541-3. PubMed ID: 7180833
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 6. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T, Niitani H, Furue H, Tsukagoshi S, Kanamaru R, Hasegawa K, Akazawa S, Yoneda S, Tominaga T, Sasaki T.
    Gan To Kagaku Ryoho; 1995 Feb 15; 22(2):259-71. PubMed ID: 7857102
    [Abstract] [Full Text] [Related]

  • 7. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG, Balcerzak SP, Kraut EH.
    Cancer Res; 1993 Oct 15; 53(20):4843-9. PubMed ID: 8402671
    [Abstract] [Full Text] [Related]

  • 8. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I, Bench K, Beijnen JH, Bruntsch U, Cavalli F, de Jong J, Groot Y, van Tellingen O, Wanders J, Sessa C.
    Clin Cancer Res; 1996 Oct 15; 2(10):1717-23. PubMed ID: 9816122
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF, O'Dwyer PJ.
    Cancer Res; 1994 Mar 01; 54(5):1220-6. PubMed ID: 8118810
    [Abstract] [Full Text] [Related]

  • 20. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ, Budman DR, Young RR, Kreis W, Ingram R, Schulman P, Cherny RC, Wright J, Behr J, Snow C, Schacter LP.
    Bone Marrow Transplant; 1996 Nov 01; 18(5):851-6. PubMed ID: 8932836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.